Efficacy and Cost-Effectiveness of Anti-VEGF for Treating Diabetic Retinopathy in the Indian Population

References

• Maguire MG, Martin DF, Ying GS, et al. Five-year outcomes with anti–vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751–1761. doi:10.1016/j.ophtha.2016.03.045
   PubMed Web of Science ®Google Scholar
• Kozak I, Shoughy SS, Stone DU. IntravitrealAntiangiogenic therapy of uveitic macular: a review. J Ocul Pharmacol Ther. 2017;33(4):235–239. doi:10.1089/jop.2016.0118
   PubMed Web of Science ®Google Scholar
• Scott IU, VanVeldhuisen PC, Ip MS, et al. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular due to central retinal vein occlusion: the SCORE2 Randomized Clinical Trial. J Am Med Assoc. 2017;317(20):2072–2087. doi:10.1001/jama.2017.4568
   PubMed Web of Science ®Google Scholar
• The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular Edema Two-year results from a comparative effectiveness Randomized Clinical Trial. N Engl J Med. 2015;372:1193–1203. doi:10.1056/NEJMoa1414264
   PubMed Web of Science ®Google Scholar
• Payne JF, Wykoff CC, Clark WL, et al. Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular: TREX-DME1 year outcomes. Ophthalmology. 2017;124(1):74–81. doi:10.1016/j.ophtha.2016.09.021
   PubMed Web of Science ®Google Scholar
• Jampol LM, Glassman AR, Bressler NM, et al. Anti–vascular endothelial growth factor comparative effectiveness trial for diabetic macular: additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial. JAMA Ophthalmol. 2016;134(12):2016–3698. doi:10.1001/jamaophthalmol.2016.3698
   Web of Science ®Google Scholar
• World Health Organization. Global report on diabetes. Geneva: World Health Organization; 2016:1–88. Available from: https://www.who.int/publications/i/item/9789241565257.
   Google Scholar
• Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi:10.2337/dc11-1909
   Google Scholar
• Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular. Ophthalmology. 2011;118(4):609–614. doi:10.1016/j.ophtha.2010.12.033
   PubMed Web of Science ®Google Scholar
• Mondal LK, Bhaduri G, Bhattacharya B. Biochemical scenario behind initiation of diabetic retinopathy in type 2 diabetes mellitus. Indian J Ophthalmol. 2018;66(4):535–540. doi:10.4103/ijo.IJO_1121_17
   PubMed Web of Science ®Google Scholar
• Choudhuri S, Dutta D, Sen A, et al. Role of N–epsilon-carboxy methyl lysine, advanced glycation end products and reactive oxygen species for the development of nonproliferative and proliferative retinopathy in type 2 diabetes mellitus. Mol Vis. 2013;19:100–113.
   Web of Science ®Google Scholar
• Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by new colorimetric method. Clin Chim Acta. 1978;90:37–43. doi:10.1016/0009-8981(78)90081-5
   PubMed Web of Science ®Google Scholar
• Pramanik S, Ganguly U, Khemka VK, Banerjee A. Decreased glucose-6-phosphate dehydrogenase activity along with oxidative stress affects visual contrast sensitivity in alcoholics. Alcohol. 2018;73:17–24. doi:10.1016/j.alcohol.2018.03.007
   Web of Science ®Google Scholar
• Virgili G, Parravano M, Menchini F, et al. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev. 2014;24(10):1–113.
   Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular. Ophthalmology. 2011;118(4):615–625. doi:10.1016/j.ophtha.2011.01.031
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular: results from 2 phase 111 randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. doi:10.1016/j.ophtha.2011.12.039
   PubMed Web of Science ®Google Scholar
• Elman MJ, Ayala A, Bressler NM, et al. IntravitrealRanibizumab for diabetic macular with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122(2):375–381. doi:10.1016/j.ophtha.2014.08.047
   PubMed Web of Science ®Google Scholar
• Azad R, Chandra P, Gupta R. The economic implications of use of anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol. 2007;55(6):441–443. doi:10.4103/0301-4738.36479
   Google Scholar
• Shanmugam PM. Changing paradigms of anti-VEGF in the Indian Scenario. Indian J Ophthalmol. 2014;62(1):88–92. doi:10.4103/0301-4738.126189
   PubMed Web of Science ®Google Scholar
• Gross JG, Glassman AR, Jampol LM, et al.; Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a Randomized Clinical Trial. JAMA. 2015;314(20):2137–2146. doi:10.1001/jama.2015.15217
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105(6):998–1003. doi:10.1016/S0161-6420(98)96025-0
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274(33):23463–23467. doi:10.1074/jbc.274.33.23463
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW, et al.; The Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077.e35. doi:10.1016/j.ophtha.2010.02.031
   PubMed Web of Science ®Google Scholar
• Mukhamala L, Bhagat N, Zarbin MA. Practical lessons from Protocol 1 for the management of diabetic macular edema. Dev Ophthalmol. 2017;60:91–108.
   Google Scholar
• Heier JS, Bressler NM, Avery RL, et al.; American Society of Retina Specialists Anti-VEGF for Diabetic Macular Edema comparative effectiveness panel. Comparison of afliberceft, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice. JAMA Ophthalmol. 2016;134(1):95–99. doi:10.1001/jamaophthalmol.2015.4110
   PubMed Web of Science ®Google Scholar
• Paine SK, Mondal LK, Borah PK, et al. Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy. Mol Vis. 2017;23:356–363.
   Web of Science ®Google Scholar
• Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular (BOLT Study) Study 12 month data: report 2. Ophthalmology. 2010;117(6):1078–1086. doi:10.1016/j.ophtha.2010.03.045
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al.; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular: two-year results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016;123(6):1351–1360. doi:10.1016/j.ophtha.2016.02.022
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796–1806. doi:10.1001/archopht.1985.01050120030015
   PubMedGoogle Scholar
• Ceravolo I, Oliverio GW, Alibrandi A, et al. The application of structural retinal biomarkers to evaluate the effect of intravitreal ranibizumab and dexamethasone intravitreal implant on treatment of diabetic macular edema. Diagnostics. 2020;10:413. doi:10.3390/diagnostics10060413
   Web of Science ®Google Scholar
• Vujosevic S, Torresin T, Berton M, et al. Diabetic macular edema with and without subfoveal neuroretinal detachment: two different morphologic and functional entities. Am J Ophthalmol. 2017;181:149–155. doi:10.1016/j.ajo.2017.06.026
   Web of Science ®Google Scholar
• Meduri A, Oliverio GW, Trombetta L, et al. Optical coherence tomography predictors of favourable functional response in naïve diabetic macular edema eyes treated with dexamethasone implants as first-line agent. J Ophthalmol. 2021;2021:1–5. doi:10.1155/2021/6639418
   Web of Science ®Google Scholar